• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.20% Nasdaq Up0.41%

    Idera Pharmaceuticals, Inc. (IDRA)

    3.03 Up 0.10(3.41%) Oct 9, 4:00PM EDT
    ProfileGet Profile for:
    Idera Pharmaceuticals, Inc.
    167 Sidney Street
    Cambridge, MA 02139
    United States - Map
    Phone: 617-679-5500
    Fax: 617-679-5592
    Website: http://www.iderapharma.com

    Index Membership:N/A
    Full Time Employees:45

    Business Summary 

    Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology. The company’s lead drug candidate includes IMO-8400, which is in Phase 1/2 clinical trials for the treatment of Waldenström’s Macroglobulinemia, diffuse large B-cell lymphoma, and Duchenne muscular dystrophy, as well as in Phase 2 clinical trial for the treatment of dermatomyositis. Its products also comprise IMO-9200, a drug candidate in Phase 1 clinical trial for use in selected autoimmune disease indications; and IMO-2055/IMO-2125 that are in Phase 1/2 clinical trials for applications as immune therapies for the treatment of cancer. In addition, the company is developing GSOs to turn off the messenger RNA associated with disease causing genes. It has license and research collaboration agreement with Merck & Co. to research, develop, and commercialize vaccine adjuvants containing TLR7, TLR8, and TLR9 agonists in the fields of cancer, infectious diseases, and Alzheimer’s disease; and an agreement with Abbott Molecular Inc. for the development of an in vitro companion diagnostic test. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Idera Pharmaceuticals, Inc.

    Corporate Governance 
    Idera Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Oct 1, 2015 is 8. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 10; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Vincent J. Milano , 51
    Chief Exec. Officer, Pres and Director
    Mr. Louis J. Arcudi III, MBA, 54
    Chief Financial Officer, Sr. VP of Operations and Treasurer
    Dr. Sudhir Agrawal D.Phil., F.R.S.C., 61
    Pres of Research and Director
    Mr. Julian C. Baker , 48
    Exec. Director of Market Devel. and Director
    Mr. Robert A. Doody Jr.,
    VP of Investor Relations & Corp. Communications
    Mr. Mark J. Casey , 51
    Sr. VP, Gen. Counsel and Sec.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders